mRNA cancer vaccine - Hanmi Pharmaceutical
Latest Information Update: 28 Aug 2023
At a glance
- Originator Hanmi Pharmaceutical
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 22 Aug 2023 mRNA cancer vaccine - Hanmi Pharmaceutical is available for licensing as of 22 Aug 2023. https://rnd.hanmipharm.com/pipeline/snapshot
- 14 Apr 2023 Preclinical trials in Cancer in South Korea (Parenteral), prior to April 2023
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)